Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients
出版年份 2015 全文链接
标题
Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients
作者
关键词
-
出版物
LEUKEMIA & LYMPHOMA
Volume 57, Issue 1, Pages 125-128
出版商
Informa UK Limited
发表日期
2015-05-02
DOI
10.3109/10428194.2015.1046867
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Thrombopoiesis
- (2015) Kenneth Kaushansky SEMINARS IN HEMATOLOGY
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
- (2014) Ramy A. Abdelrahman et al. BRITISH JOURNAL OF HAEMATOLOGY
- An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
- (2014) A Tefferi et al. LEUKEMIA
- An Immune Dysregulation in MPN
- (2014) Giovanni Barosi Current Hematologic Malignancy Reports
- Therapy for myeloproliferative neoplasms: when, which agent, and how?
- (2014) H. L. Geyer et al. Hematology-American Society of Hematology Education Program
- Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
- (2013) Ruben A Mesa et al. Journal of Hematology & Oncology
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis
- (2013) Vibe Skov et al. LEUKEMIA & LYMPHOMA
- JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
- (2012) Fabio P. S. Santos et al. Anti-Cancer Agents in Medicinal Chemistry
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis
- (2011) Vibe Skov et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
- (2011) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
- (2010) C. Nielsen et al. HAEMATOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now